| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Genetic Markers Associated With Risk for Ulcerative Colitis Identified PITTSBURGH, Pa -- January 5, 2008 -- Researchers have identified genetic markers associated with risk for ulcerative colitis. The findings are published early online and in an upcoming issue of the journal Nature Genetics. Richard H. Duerr, MD, University of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, Pennsylvania, and colleagues performed a genome-wide association study of hundreds of thousands of genetic markers using DNA samples from 1,052 individuals with ulcerative colitis and pre-exisiting data from 2,571 controls. All were of European ancestry and residing in North America. Several genetic markers on chromosomes 1p36 and 12q15 showed highly significant associations with ulcerative colitis, and the association evidence was replicated in independent European ancestry samples from North America and southern Italy. Nearby genes implicated as possibly playing a role in ulcerative colitis include the ring finger protein 186 (RNF186), OTU domain containing 3 (OTUD3), and phospholipase A2, group IIE (PLA2G2E) -- genes on chromosome 1p36, and the interferon, gamma (IFNG), interleukin 26 (IL26), and interleukin 22 (IL22) genes on chromosome 12q15. The study also found highly suggestive associations between ulcerative colitis and genetic markers on chromosome 7q31 within or near the laminin, beta 1 (LAMB1) gene. "My laboratory is focused on studying the genetic basis for IBD. Through genetic mapping, we and our collaborators are successfully identifying regions of the genome that contain IBD genes," said Dr. Duerr. "The next steps are to understand the functional significance of IBD-associated genetic variants, and then to develop new treatments that specifically target biological pathways implicated by the genetic discoveries. The overall goal of this work is to improve the lives of the millions of patients worldwide that suffer from IBD." SOURCE: University of Pittsburgh Schools of the Health Sciences
|